









Mercado
/
Acciones
/
nasdaq-gh
/

Guardant Health Inc

61.400USD

+0.120+0.20%

Cierre 08/22, 16:00（ET）Cotizaciones retrasadas 15 min

7.64BCap. mercado

PérdidaP/E TTM



Guardant Health Inc

61.400

+0.120+0.20%

Descripción general Compañía Finanzas

Finanzas

Más Datos de Guardant Health Inc Compañía

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Información de la empresa

Símbolo de cotizaciónGH

Nombre de la empresaGuardant Health Inc

Fecha de salida a bolsaOct 04, 2018

Director ejecutivoDr. Amirali Talasaz, Ph.D.

Número de empleados1999

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 04

Dirección3100 Hanover Street

CiudadPALO ALTO

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94304

Teléfono18556988887

Sitio Webhttps://guardanthealth.com/

Símbolo de cotizaciónGH

Fecha de salida a bolsaOct 04, 2018

Director ejecutivoDr. Amirali Talasaz, Ph.D.

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Helmy A. Eltoukhy, Ph.D.

Chairperson of the Board, Co-Chief Executive Officer

2.75M

+0.43%

Dr. Amirali Talasaz, Ph.D.

Co-Chief Executive Officer, Director

2.50M

-3.40%

Dr. Darya Chudova

Chief Technology Officer

80.44K

+1.88%

Mr. John Gomes Saia

Chief Legal Officer, Corporate Secretary

44.82K

+2.88%

Mr. Craig Eagle, M.D.

Chief Medical Officer

36.79K

+4.75%

Ms. Vijaya V. Gadde

Independent Director

24.31K

+37.83%

Ms. Myrtle Stephens Potter

Independent Director

18.24K

+0.24%

Mr. Kumud Kalia

Chief Information Officer

17.82K

+8.04%

Ms. Meghan V. Joyce

Independent Director

11.28K

+0.60%

Mr. Musa Tariq

Independent Director

7.46K

+1.83%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Helmy A. Eltoukhy, Ph.D.

Chairperson of the Board, Co-Chief Executive Officer

2.75M

+0.43%

Dr. Amirali Talasaz, Ph.D.

Co-Chief Executive Officer, Director

2.50M

-3.40%

Dr. Darya Chudova

Chief Technology Officer

80.44K

+1.88%

Mr. John Gomes Saia

Chief Legal Officer, Corporate Secretary

44.82K

+2.88%

Mr. Craig Eagle, M.D.

Chief Medical Officer

36.79K

+4.75%

Ms. Vijaya V. Gadde

Independent Director

24.31K

+37.83%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology

150.56M

74.00%

Biopharma and data

45.38M

22.30%

Screening

5.68M

2.79%

Licensing and other

1.86M

0.91%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

193.61M

95.15%

International

9.86M

4.85%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology

150.56M

74.00%

Biopharma and data

45.38M

22.30%

Screening

5.68M

2.79%

Licensing and other

1.86M

0.91%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

6.73%

Capital International Investors

3.99%

Baillie Gifford & Co.

3.86%

Deep Track Capital LP

3.41%

Otro

72.28%

Accionistas

Proporción

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

6.73%

Capital International Investors

3.99%

Baillie Gifford & Co.

3.86%

Deep Track Capital LP

3.41%

Otro

72.28%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

48.60%

Investment Advisor/Hedge Fund

26.83%

Hedge Fund

19.40%

Individual Investor

4.54%

Bank and Trust

2.25%

Research Firm

1.91%

Sovereign Wealth Fund

1.83%

Pension Fund

1.17%

Family Office

0.03%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

759

134.16M

107.59%

-14.14M

2025Q1

783

130.34M

105.23%

-16.59M

2024Q4

746

130.16M

105.47%

-20.09M

2024Q3

780

137.29M

111.53%

-9.70M

2024Q2

801

127.50M

103.74%

-18.45M

2024Q1

826

124.00M

101.88%

-12.71M

2023Q4

856

120.18M

99.30%

-14.26M

2023Q3

867

117.78M

100.31%

-19.15M

2023Q2

890

119.83M

102.55%

+840.96K

2023Q1

908

101.46M

98.78%

-16.37M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

12.05M

9.73%

+28.83K

+0.24%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.61M

6.95%

-284.70K

-3.20%

Mar 31, 2025

Capital International Investors

5.15M

4.16%

+674.48K

+15.08%

Mar 31, 2025

Baillie Gifford & Co.

5.06M

4.09%

-388.09K

-7.12%

Mar 31, 2025

Deep Track Capital LP

5.44M

4.39%

-975.85K

-15.20%

Mar 31, 2025

Two Sigma Investments, LP

4.19M

3.38%

-12.65K

-0.30%

Mar 31, 2025

Eventide Asset Management, LLC

3.57M

2.88%

-241.20K

-6.33%

Mar 31, 2025

Invesco Advisers, Inc.

2.61M

2.11%

+1.32M

+102.00%

Mar 31, 2025

Cadian Capital Management LP

4.60M

3.71%

-626.48K

-12.00%

Mar 31, 2025

Citadel Advisors LLC

3.60M

2.9%

+2.12M

+142.72%

Mar 31, 2025

ETFs relacionados

Actualizado: mié., 6 de ago

Nombre

Proporción

ARK Genomic Revolution ETF

6.73%

Franklin Genomic Advancements ETF

3.94%

Global X Genomics & Biotechnology ETF

3.38%

First Trust Nasdaq Lux Digi Health Solutions ETF

2.7%

ROBO Global Healthcare Technology & Innovation ETF

2.04%

Invesco Dorsey Wright Healthcare Momentum ETF

1.83%

BNY Mellon Innovators ETF

1.64%

SPDR S&P Health Care Services ETF

1.52%

iShares Health Innovation Active ETF

1.24%

ARK Innovation ETF

1.05%

ARK Genomic Revolution ETF

Proporción6.73%

Franklin Genomic Advancements ETF

Proporción3.94%

Global X Genomics & Biotechnology ETF

Proporción3.38%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporción2.7%

ROBO Global Healthcare Technology & Innovation ETF

Proporción2.04%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción1.83%

BNY Mellon Innovators ETF

Proporción1.64%

SPDR S&P Health Care Services ETF

Proporción1.52%

iShares Health Innovation Active ETF

Proporción1.24%

ARK Innovation ETF

Proporción1.05%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

